Last 31 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -190.13 | — | — | — | 359.36 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.12 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 10.45 | 10.52 | 8.50 | 6.66 | 7.85 | 4.95 | 4.93 | 5.03 | 5.15 | 5.18 | 4.26 | 4.96 | 6.80 | 6.57 | 7.16 | 6.55 | 9.77 | 8.95 | 13.36 | 38.86 | 30.25 |
| — | +112.6% | +72.3% | +32.4% | +52.3% | -4.5% | +15.9% | +1.4% | -24.2% | -21.1% | -40.5% | -24.4% | -30.4% | -26.6% | -46.4% | -83.1% | -67.7% | -24.7% | — | — | — | |
| P/B Ratio | 14.25 | — | 22.42 | 12.60 | 14.31 | 9.92 | 9.44 | 8.86 | 8.03 | 7.05 | 5.02 | 5.55 | 4.83 | 12.54 | 6.41 | 5.15 | 4.33 | 5.66 | 6.33 | 4.06 | 10.73 |
| — | — | +137.4% | +42.2% | +78.1% | +40.6% | +87.9% | +59.7% | +66.4% | -43.8% | -21.6% | +7.7% | +11.3% | +121.7% | +1.3% | +26.9% | -59.6% | +3.5% | +42.0% | +53.2% | +166.3% | |
| P/FCF | 99.31 | — | — | 181.32 | 26.45 | 53.10 | — | — | — | — | 19.39 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 2595.85 | — | — | 661.57 | 121.61 | 614.19 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | 351.48 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.87 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.7% | 82.8% | 81.9% | 81.0% | 80.8% | 81.7% | 79.4% | 77.1% | 77.0% | 74.0% | 74.2% | 64.0% | 78.6% | 81.8% | 84.2% | 83.9% | 84.4% | 85.6% | 81.2% | 39.4% | 100.0% |
| — | +1.4% | +3.2% | +5.0% | +5.0% | +10.3% | +6.9% | +20.4% | -2.0% | -9.5% | -11.9% | -23.7% | -6.9% | -4.4% | +3.8% | +113.2% | -15.6% | -14.4% | — | — | — | |
| Operating Margin | -4.2% | -24.1% | -39.5% | -3.1% | 2.0% | -3.9% | -13.6% | -24.4% | -14.0% | -31.1% | -38.2% | -46.8% | -52.7% | -64.7% | -85.9% | -122.4% | -175.1% | -179.8% | -253.9% | -1452.4% | -856.5% |
| — | -518.2% | -190.3% | +87.4% | +113.9% | +87.5% | +64.4% | +48.0% | +73.4% | +51.9% | +55.5% | +61.7% | +69.9% | +64.0% | +66.2% | +91.6% | +79.6% | +47.1% | — | — | — | |
| Net Margin | -4.5% | -38.1% | -494.2% | -3.8% | 2.2% | -4.6% | -13.2% | -23.9% | -15.8% | -31.6% | -36.5% | -51.3% | -49.4% | -197.5% | -95.4% | -130.5% | -190.1% | -154.0% | -283.9% | 1833.8% | -942.2% |
| — | -731.7% | -3657.3% | +83.9% | +113.9% | +85.5% | +64.0% | +53.3% | +68.1% | +84.0% | +61.7% | +60.7% | +74.0% | -28.2% | +66.4% | -107.1% | +79.8% | +61.4% | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.6% | -57.9% | -283.6% | -1.9% | 1.1% | -2.4% | -6.4% | -10.4% | -6.2% | -10.6% | -10.5% | -13.8% | -13.6% | -67.4% | -21.3% | -23.4% | -25.5% | -24.5% | -32.0% | 65.2% | -61.9% |
| — | -2314.0% | -4333.9% | +81.8% | +117.2% | +77.4% | +38.9% | +24.5% | +54.5% | +84.2% | +50.8% | +41.1% | +46.8% | -174.8% | +33.4% | -135.9% | +58.8% | +35.9% | +3.3% | +356.1% | -269.3% | |
| ROA | -3.1% | -6.9% | -91.2% | -0.7% | 0.4% | -0.8% | -2.2% | -3.6% | -2.1% | -3.8% | -3.9% | -5.5% | -4.3% | -19.1% | -8.8% | -10.2% | -10.8% | -9.4% | -12.8% | 21.7% | -19.5% |
| — | -739.0% | -4126.2% | +80.2% | +117.9% | +77.9% | +44.6% | +35.3% | +50.3% | +80.3% | +55.7% | +45.9% | +60.1% | -103.6% | +31.3% | -146.8% | +44.7% | +49.9% | +41.4% | +211.7% | -35.0% | |
| ROIC | -5.0% | -9.7% | -16.4% | -1.0% | 0.6% | -1.1% | -3.5% | -5.6% | -3.0% | -6.6% | -7.8% | -9.0% | -10.4% | -19.9% | -19.4% | -20.3% | -25.5% | -38.4% | -31.4% | -72.1% | -637.8% |
| — | -783.3% | -374.0% | +81.7% | +119.4% | +83.4% | +55.7% | +37.5% | +71.3% | +66.9% | +59.9% | +55.9% | +59.3% | +48.2% | +38.1% | +71.8% | +96.0% | +63.7% | +65.1% | -40.7% | -2475.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.02 | — | 1.34 | 1.02 | 1.09 | 1.25 | 1.36 | 1.41 | 1.37 | 1.38 | 1.31 | 1.24 | 1.14 | 3.92 | 0.01 | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | 0.05 |
| — | — | -1.8% | -27.9% | -20.3% | -9.6% | +3.7% | +13.6% | +19.6% | -64.7% | +9296.5% | +7944.4% | +9188.5% | +19002.9% | -37.8% | -29.2% | -75.0% | -33.3% | -3.3% | +14.7% | +74.0% | |
| Debt / EBITDA | 151.54 | — | — | 211.98 | 36.79 | 298.87 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.67 | 2.86 | 2.09 | 2.67 | 3.31 | 3.13 | 3.22 | 3.10 | 3.34 | 3.28 | 3.68 | 4.45 | 5.20 | 6.59 | 3.53 | 2.94 | 4.19 | 3.26 | 4.49 | 3.91 | 3.91 |
| — | -8.8% | -35.2% | -13.9% | -0.9% | -4.4% | -12.4% | -30.3% | -35.8% | -50.3% | +4.2% | +51.5% | +24.1% | +102.2% | -21.5% | -24.9% | +7.4% | -58.6% | -27.7% | -69.5% | -46.9% | |
| Quick Ratio | 2.55 | 2.74 | 1.99 | 2.55 | 3.16 | 2.97 | 3.04 | 2.93 | 3.15 | 3.09 | 3.47 | 4.19 | 4.91 | 6.44 | 3.39 | 2.85 | 4.06 | 3.16 | 4.45 | 3.88 | 3.91 |
| — | -7.8% | -34.5% | -12.9% | +0.2% | -3.9% | -12.3% | -30.2% | -35.7% | -52.0% | +2.4% | +47.0% | +20.9% | +103.9% | -23.7% | -26.4% | +3.9% | -59.8% | -28.5% | -69.7% | -46.9% | |
| Interest Coverage | -0.49 | -6.99 | -217.38 | -0.38 | 0.83 | -0.52 | -2.80 | -5.81 | -2.87 | -5.73 | -5.89 | -8.94 | -5.53 | -18.79 | -6.06 | -7.33 | -7.99 | -7.64 | -8.70 | 16.28 | -7.31 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 31 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MIRM stock.
Mirum Pharmaceuticals, Inc.'s current P/E is -190.1x. The average P/E over the last 1 quarters is 359.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Mirum Pharmaceuticals, Inc.'s current operating margin is -4.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Mirum Pharmaceuticals, Inc.'s business trajectory between earnings reports.